• February 6, 2013
    MADISON, N.J.--(BUSINESS WIRE)--ZoetisTM (NYSE:ZTS), formerly the animal health business unit of Pfizer Inc., today announced the closing of its previously announced initial public offering. The offering of 99,015,000 shares of its Class A common stock included 12,915,000 shares of Class A common stock that were sold pursuant to the underwriters’ option to purchase additional shares, which was exercised in full prior to the closing.Zoetis did not receive any of the proceeds of the offering. Following the completion of themore...
  • January 31, 2013
    MADISON, N.J.--ZoetisTM, formerly the animal health business unit of Pfizer Inc., today announced the pricing of its initial public offering of 86,100,000 shares of its Class A common stock at $26 per share. The shares are expected to begin trading tomorrow, Feb. 1, on the New York Stock Exchange under the symbol “ZTS.” Zoetis will not receive any of the proceeds of the offering. Following the completion of the initial public offering,more...
  • November 1, 2012
    Australian horse owners who are battling against the deadly Hendra virus received an important boost today with the introduction of Equivac® HeV vaccine. The Equivac® HeV vaccine will be available for use under permit by accredited veterinarians thanks to an international public-private partnership created to make this important new vaccine accessible. The vaccine, launched by Pfizer Animal Health, will help prevent the spread of the Hendramore...
  • October 3, 2012
    Pfizer Animal Health announces the launch of Poulvac E coli, the first spray vaccine against avian pathogenic Escherichia coli (APEC) for the poultry industry to be approved in the European Union. This new vaccine is based on a European E. coli isolate, and has been shown to provide a broad protection against field infections found in the region. It can be administered from one day of age, and studies have shown that it generates amore...
  • August 13, 2012
    NEW YORK--Pfizer Inc. (NYSE: PFE) today announced that its subsidiary, Zoetis™ Inc. (zō-EH-tis), filed a registration statement with the U.S. Securities and Exchange Commission for a potential initial public offering (IPO) of Class A common stock. The offering is expected to represent an ownership stake of up to 20 percent. Prior to completion of the offering, which is targeted for the first half of 2013, Pfizer will transfer its animal healthmore...
  • July 25, 2012
    VANCOUVER, British Columbia--Data to be presented this week at the 7th World Congress of Veterinary Dermatology (WCVD) Meeting 2012 will report new insights into the disease pathways involved in allergic conditions in dogs, Pfizer Animal Health announced today. Researchers with Pfizer Animal Health’s Global Therapeutic Research Group have, for the first time, identified a potential role for the cytokine IL-31 in triggering itchmore...
  • July 25, 2012
    VANCOUVER, British Columbia--Pfizer Animal Health will present data from discovery studies validating specific pathways of allergic skin disease in dogs and studies evaluating novel molecules targeting these pathways at the 7th World Congress of Veterinary Dermatology (WCVD) Meeting 2012 in Vancouver, British Columbia, from July 24–28. Approximately six presentations related to Pfizer’s research and development program in veterinary dermatologymore...
  • July 23, 2012
    MADISON, N.J.--Pfizer Animal Health (PAH) has launched two educational web sites to communicate advancements in veterinary dermatology and help improve the discussions between veterinarians and pet owners about allergic skin conditions. The two sites—www.mypetitches.com and www.itchcycle.com —bring visitors the latest research and news from the dermatological community and highlight new information about PAH’s portfolio ofmore...
  • June 7, 2012
    NEW YORK--Pfizer Inc. (NYSE: PFE) today announced the next steps in the strategic alternatives review process for the company's Animal Health business. Preparations are underway to file a registration statement in the U.S. for a potential initial public offering (IPO) of a minority ownership stake in the new company. Pfizer expects to provide details regarding the proposed transaction as part of its 2012 second quarter earnings announcement.more...
  • April 19, 2012
    PARIS, France--The famous Auzoux Horse, one of the first veterinary teaching aids of its kind, has been restored to its former glory thanks to a €50,000 grant from Pfizer Animal Health. The papier-mâché model dates back to 1846 and was initially created to allow veterinary students to mimic a dissection without having to use an actual cadaver, an unpleasant and dangerous choice in an era when it was not uncommon for people to die ofmore...